Pakistan
Tuberculosis profile
| High TB burden | High MDR-TB burden |
Population  2012 179 million
Estimates of TB burden * 2012 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 62 (27–110) 34 (15–61)
Mortality (HIV+TB only) 1.2 (0.83–1.3) 0.66 (0.46–0.75)
Prevalence  (includes HIV+TB) 670 (320–1 100) 376 (181–641)
Incidence  (includes HIV+TB) 410 (340–490) 231 (190–276)
Incidence (HIV+TB only) 3.8 (3.1–4.6) 2.1 (1.7–2.6)
Case detection, all forms (%) 65 (54–78)    
TB case notifications 2012        
New cases   (%) Retreatment cases (%)
Smear-positive 110 545 (42) Relapse 6 095 (52)
Smear-negative 109 425 (42) Treatment after failure 847 (7)
Smear-unknown / not done 0 (0) Treatment after default 1 241 (11)
Extrapulmonary 41 410 (16) Other 3 534 (30)
Other 0 (0)      
Total new 261 380   Total retreatment 11 717  
           
Other (history unknown) 0        
Total new and relapse 267 475   Total cases notified 273 097  
New cases Smear-positive Smear-negative/ unknown/
not done
Extrapulmonary
M:F ratio 1.1 1.0 0.8
Age < 15 3 947 13 884 8 328
Laboratories 2012
Smear (per 100 000 population) 0.8
Culture (per 5 million population) 0.2
Drug susceptibility testing (per 5 million population) 0.1
Is second-line drug susceptibility testing available? Yes, in country
Treatment success rate 2011 (%)        
New smear-positive and/or culture-positive 92   Is rifampicin used
throughout treatment for
new patients?
Yes
New smear-negative/extrapulmonary 93  
Retreatment 80  
TB/HIV 2012 Number (%)
TB patients with known HIV status 10 419 (4)
HIV-positive TB patients 30 (<1)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 30 (100)
HIV-positive TB patients on antiretroviral therapy (ART) 22 (73)
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Estimates of MDR-TB burden 2012*   New   Retreatment
% of TB cases with MDR-TB 3.5 (0.1–12) 32 (7.5–56)
MDR-TB cases among notified pulmonary
TB cases
7 700 (220–27 000) 3 700 (880–6 600)
Reported cases of MDR-TB 2012 New Retreatment Total
Cases tested for MDR-TB 461 (<1%) 154 (1%) 4 198
Laboratory-confirmed MDR-TB cases 19 55 1 602
Patients started on MDR-TB treatment     1 045
Financing TB control 2013
National TB programme budget (US$ millions) 73
% Funded domestically 5%
% Funded internationally 85%
% Unfunded 9%
***
(Rate per 100 000 population per year)
Mortality graph
___ Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
___ Prevalence

(Rate per 100 000 population per year)
Incidence graph
__ Notifications Incidence
___
___ Incidence (HIV+TB only)

Treatment success rate (%)
tx success graph
__ New smear-positive and/or culture-positive
__ New smear-negative/extrapulmonary __
Retreatment

(Number of patients)
CPT ART graph
__ HIV-positive TB patients
__ on CPT __ on ART

Total budget (US$ millions)
Budget funding Graph
__ Funded domestically __ Funded internationally
__ Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 * Ranges represent uncertainty intervals Generated: 2014-04-23 Data: www.who.int/tb/data